Biotechnology firm, tCheck, has sold 8,000+ cost-effective and efficacious testing devices helping consumers to make better informed decisions.
WEST PALM BEACH, FL, December 10, 2020 /24-7PressRelease/ — BVE Select Fund, LLC, a Bonaventure Equity managed venture investor, is pleased to announce its investment in Engineered Medical Technologies, Inc. (“tCheck”), a biotechnology firm focused on developing and delivering efficient, cost-effective and efficacious testing technology to all.
Established in 2015 by a team of designers, engineers, and scientists, tCheck simplifies spectroscopy and provides commercial grade testing devices to businesses, growers and individual consumers. The tCheck Classic, tCheck 2, and accessory products, solve a problem common to those selling or consuming cannabis containing products, that being the ability to confirm the amount of cannabinoid in a product. Using just two drops of an infused oil, tCheck’s handheld device delivers results in just a few minutes. To date, tCheck has sold more than 8,000 testing devices.
“It is our primary mission to empower individuals to make sound decisions about their health. We believe, as does most of the scientific community and general population, that cannabis is medicine and has the potential to help millions of people,” said Co-founder and CEO Peichen Chang. He continued, “Through the use of our devices, consumers and those selling to consumers, are able to quickly and cost-effectively confirm consumption amounts and make confident, better informed decisions.”
Bonaventure Equity (“BVE”), founded in 2014 by Ross O’Brien, is a boutique venture capital platform that provides capital, resources and unparalleled access to strategic and regulatory relationships. With decades of investing in, building, growing and exiting private companies, BVE provides leading entrepreneurs with the capital and resources they require to build the great businesses of tomorrow.
“We are very excited to add tCheck to the BVE Select portfolio. It is our firm’s mission to create $1 billion in value and positively impact 1 billion lives. We fulfil this mission by investing in innovative, high-achieving management teams, just like the founders leading tCheck,” said Ross O’Brien, Founder and CEO. He continued, “We are very pleased to close our first cannabis venture fund this year and timing that with this investment is the icing on the cake. It was serendipitous for this particular deal to come through Entrepreneur’s Elevator Pitch series as we are partnering with Entrepreneur to launch their first venture capital fund which will have a much broader investment mandate. This new fund, Entrepreneur Select, will invest in companies from more traditional sectors and use bespoke practices to source the most promising and tenacious entrepreneurs. There is a lot to look forward to in 2021.”
About Bonaventure Equity
Established in 2014, Bonaventure Equity, LLC is a Venture Capital investor funding the next generation of innovative companies delivering economic, societal, cultural and healthcare benefits through leading technologies, services and science. We partner with exceptional entrepreneurial management teams built on a foundation of execution, collaborative leadership, and an unwavering drive to deliver positive global impact. The power of our investment platform delivers value beyond just capital through our operations back office infrastructure. Our unparalleled access to global thought leaders, policymakers and advisors is all designed to accelerate growth for the companies we back.
About Engineered Medical Technologies
Founded in 2015, Engineered Medical Technologies (“tCheck”) is a biotechnology company that simplifies spectroscopy and delivers efficient and efficacious commercial grade testing devices to the hands of every consumer. Established by a team of engineers, designers, and scientists, tCheck empowers individuals, businesses, and growers in a variety of industries, with data to quickly and cost-effectively make better informed decisions.
If you would like additional information, please contact Maggie Kelly at [email protected] or 561-308-3293.
For the original version of this press release, please visit 24-7PressRelease.com here